Issue of Equity and Total Voting Rights

RNS Number : 3690P

Evgen Pharma PLC

31 August 2017

 

For immediate release	31 August 2017

 

 

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")

Issue of Equity and Total Voting Rights

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that it has received notice to exercise options over 837,600 ordinary shares in the Company.

The options were granted under individual option agreements and have exercise prices of 5 pence per share in respect of 628,000 options and 0.875 pence per share in respect of 209,600 options.  Accordingly, the Company has issued and allotted 837,600 new ordinary shares of 0.25 pence each ("New Ordinary Shares").  The New Ordinary Shares rank pari passu with the Company's existing issued ordinary shares.  Application has been made to admit the New Ordinary Shares to trading on AIM and dealings in these shares are expected to commence at 8.00 a.m. on 6 September 2017. 

There are no shares held in treasury, therefore following the admission of the New Ordinary Shares the total number of voting rights in the Company will be 74,110,191.  This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest under the Disclosure and Transparency Rules.

Enquiries:

Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com	c/o [phone]
Buchanan Mark Court, Sophie Cowles, Stephanie Watson		[phone]
Northland Capital Partners Limited Matthew Johnson, Gerry Beaney (Corporate Finance) John Howes, Rob Rees (Corporate Broking)		[phone]

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

 

END

 

 

IOEFBLLXDVFFBBD